Pancreatic Cancer – Landscape & Forecast – Disease Landscape & Forecast

Pancreatic cancer remains difficult to treat owing to the lack of treatment options—primarily surgery, radiation, and chemotherapy. Pancreatic adenocarcinoma represents the vast majority of pancreatic cancer, whereas pancreatic neuroendocrine tumors (PNETs) comprise only a small subset. First-line treatment for advanced or metastatic pancreatic adenocarcinoma relies on FOLFIRINOX or gemcitabine + nanoparticle paclitaxel, while synthetic somatostatin analogues remain the cornerstone for PNET management. Second-line pancreatic adenocarcinoma treatment options include liposomal irinotecan + 5-FU + leucovorin for patients who failed gemcitabine-based therapy; Merus’s zenocutuzumab is an option for previously treated patients with NRG1 fusion-positive pancreatic adenocarcinoma, and AstraZeneca / Merck’s olaparib is approved as a maintenance therapy in germline BRCA-mutated cases. Despite these advancements, survival benefits remain modest, highlighting the urgent need for novel therapies. Late-phase targeted treatments such as RAS inhibitors, MEK inhibitors, and radiotherapeutics will provide better treatment options.

Questions answered:

• How large are the clinically and commercially relevant pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumor (PNET) drug-treatable populations, and how will drug-treatment rates change over the 2024-2034 forecast period?
• What is the current treatment algorithm for pancreatic adenocarcinoma and PNETs in the major markets? What are interviewed experts’ views on current therapies?
• Which are the most promising emerging therapies in the late-phase pipeline? What uptake and patient shares can late-phase pipeline agents in development for pancreatic cancer expect to secure?
• What are the key drivers and constraints in pancreatic cancer, and how will this market evolve over the forecast period?

Geography: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading medical oncologists. Survey data collected for this and other Clarivate research

Epidemiology: Diagnosed incidence by country and disease stage; clinically and market-relevant drug-treatable populations

Forecast: 10-year, annualized, drug-level sales and patient share of key pancreatic cancer therapies through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.